Successful use of posaconazole to treat invasive cutaneous fungal infection in a liver transplant patient on sirolimus

被引:8
作者
Dahlan, Randah [1 ]
Patel, Ameen [2 ]
Haider, Shariq [3 ]
机构
[1] McMaster Univ, Dept Internal Med, Hamilton, ON L8S 4L8, Canada
[2] Hamilton Hlth Sci, Div Gen Internal Med, Hamilton, ON, Canada
[3] Hamilton Hlth Sci, Div Infect Dis, Hamilton, ON, Canada
关键词
Cutaneous fungal infections; Liver transplantation; Posaconazole; Sirolimus; ORAL POSACONAZOLE; DRUG-INTERACTIONS; VORICONAZOLE; PHARMACOKINETICS; HEALTHY;
D O I
10.1155/2012/272197
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Fungi are an important and common cause of cutaneous infections affecting solid organ transplant recipients. These infections can represent a primary site of infection with the potential for dissemination, or a manifestation of metastatic infection. The high morbidity and mortality associated with these infections necessitates urgent therapy with antifungal drugs; however, the interaction between these drugs and immunosuppressive therapies can be a major limitation because of drug toxicity. A case of soft tissue infection of the toe caused by Fusarium chlamydosporum and Candida guilliermondii in a liver transplant patient on sirolimus, who was successfully treated with the new antifungal agent posaconazole, is described. The pharmacokinetic interactions of sirolimus and the new triazoles, and their impact on treatment choices are briefly discussed.
引用
收藏
页码:E44 / E47
页数:4
相关论文
共 17 条
[1]   Invasive fungal infections: a review of epidemiology and management options [J].
Enoch, D. A. ;
Ludlam, H. A. ;
Brown, N. M. .
JOURNAL OF MEDICAL MICROBIOLOGY, 2006, 55 (07) :809-818
[2]   Cellulitis and Nodular Skin Lesions Due to Fusarium spp in Liver Transplant: Case Report [J].
Halpern, M. ;
Balbi, E. ;
Carius, L. ;
Roma, J. ;
Gonzalez, A. C. ;
Agoglia, L. ;
Covelo, M. ;
Araujo, A. ;
Guedes, C. ;
Alves, J. ;
Enne, M. ;
Martinho, J. M. ;
Pacheco, L. .
TRANSPLANTATION PROCEEDINGS, 2010, 42 (02) :599-600
[3]  
Hong W, 2003, CHINESE MED J-PEKING, V116, P1421
[4]   Disposition of posaconazole following single-dose oral administration in healthy subjects [J].
Krieter, P ;
Flannery, B ;
Musick, T ;
Gohdes, M ;
Martinho, M ;
Courtney, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (09) :3543-3551
[5]   Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation [J].
Marty, FM ;
Lowry, CM ;
Cutler, CS ;
Campbell, BJ ;
Fiumara, K ;
Baden, LR ;
Antin, JH .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2006, 12 (05) :552-559
[6]  
Moton A, 2009, CURR MED RES OPIN, V25, P701, DOI [10.1185/03007990802644209, 10.1185/03007990802644209 ]
[7]   In vitro interaction of posaconazole with calcineurin inhibitors and sirolimus against zygomycetes [J].
Narreddy, S. ;
Manavathu, E. ;
Chandrasekar, P. H. ;
Alangaden, G. J. ;
Revankar, S. G. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (04) :701-703
[8]   Cutaneous infection by Fusarium species in healthy and Immunocompromised hosts:: Implications for diagnosis and management [J].
Nucci, M ;
Anaissie, E .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (08) :909-920
[9]   Fusarium Infections in Immunocompromised Patients [J].
Nucci, Marcio ;
Anaissie, Elias .
CLINICAL MICROBIOLOGY REVIEWS, 2007, 20 (04) :695-704
[10]   New and emerging treatments for fungal infections [J].
Pasqualotto, A. C. ;
Denning, D. W. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 61 :I19-I30